Dr. Daniel Almquist, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 269
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
ND license 17485 · AZ license 56145 -
Internal Medicine Physician
NE license 7207 · NE license 29285
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Sanford Medical Center Fargo Fargo, ND
- Sanford Bemidji Medical Center Bemidji, MN
- Perham Health Perham, MN
- Sanford Mayville Mayville, ND
- Rainy Lake Medical Center International Falls, MN
Medical groups
- Sanford Medical Center Fargo (1,225 clinicians)
- Sanford Health of Northern Minnesota (343 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 269
- Services billed
- 1,932
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 365 | 164 |
| Established patient office or other outpatient visit, 30-39 minutes | 255 | 138 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 34 | 18 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 29 | 28 |
| New patient office or other outpatient visit, 60-74 minutes | 28 | 28 |
| New patient office or other outpatient visit, 45-59 minutes | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 3 payments worth $77.40 in total to this clinician.
| Merck Sharp & Dohme LLC | $51.40 |
|---|---|
| Pfizer Inc. | $26.00 |
| Education | $77.40 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Mar 24, 2025 | Education PADCEV · ONCOLOGY · in-kind | $26.00 |
| Merck Sharp & Dohme LLC Mar 24, 2025 | Education KEYTRUDA · ONCOLOGY · in-kind | $25.70 |
| Merck Sharp & Dohme LLC Mar 24, 2025 | Education KEYTRUDA · ONCOLOGY · in-kind | $25.70 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $228,992 in research payments for these studies, mostly to the institutions running them.
- KEYMAKER-U01 Master Study# A Phase 1,2, Umbrella Study with Rolling Arms of Investigational Agents, Pembrolizumab, and Chemotherapy, Alone or in Combination, in Participants with Non-small Cell Lung Cancer NSCLC
Merck Sharp & Dohme LLC - A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With YL201 With or Without Anti-PD-L1 in Subjects With Extensive Stage Small Cell Lung Cancer
Amgen Inc. - Study name not reported
Iovance Biotherapeutics, Inc. - KEYMAKER-U01 Substudy 01G# A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab With or Without Platinum-based Chemotherapy in Treatment-Na ve Participants With Stage…
Merck Sharp & Dohme LLC - KEYMAKER-U01 Substudy 01J# A Randomized Phase 2 Umbrella Study With Rolling Arms of Investigational Agents for First-line Treatment of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer NS…
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.